# An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

> **NCT03952039** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 202 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera
- Myelofibrosis

## Interventions

- **DRUG:** FEDRATINIB
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT03952039
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2022-12-15
- **Final completion:** 2025-07-28
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952039, "An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03952039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*